ACRAF vs. Sun Pharma: Trazodone Patent Dismissed With Prejudice in Delaware
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | ACRAF S.p.A. v. Sun Pharmaceutical Industries, Inc. |
| Case Number | 1:23-cv-00295 (D. Del.) |
| Court | U.S. District Court for the District of Delaware |
| Duration | Mar 2023 – Jul 2024 ~500 days |
| Outcome | Plaintiff Win — Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | Sun Pharmaceutical’s trazodone hydrochloride formulation |
Case Overview
The Parties
⚖️ Plaintiff
Italian pharmaceutical company with a long-established portfolio in central nervous system (CNS) therapies.
🛡️ Defendant
U.S. subsidiary of Sun Pharma, one of the world’s largest specialty generic pharmaceutical manufacturers.
The Patent at Issue
This landmark case involved U.S. Patent No. 8,133,893 B2, covering purified trazodone and trazodone hydrochloride formulations. Design patents are registered with the U.S. Patent and Trademark Office (USPTO) and protect ornamental appearance rather than functional technology.
- • US 8,133,893 B2 — Purified trazodone and trazodone hydrochloride formulations
Developing a new pharmaceutical formulation?
Check if your drug formulation might infringe this or related patents before launch.
The Verdict & Legal Analysis
Outcome
On July 29, 2024, ACRAF and Sun Pharmaceutical jointly filed a stipulation of dismissal with prejudice pursuant to Fed. R. Civ. P. 41(a)(1)(A)(ii) and 41(c). The stipulation extinguished all claims, counterclaims, and affirmative defenses between the parties, with no award of costs, disbursements, or attorneys’ fees to either side. No damages were awarded. No injunctive relief was granted. The case did not proceed to trial or produce a merits-based judicial ruling on infringement or patent validity.
Legal Significance
The Federal Circuit’s analysis focused on the critical “article of manufacture” question — whether design patent damages should be based on the entire product or a specific component. The court held that the relevant article of manufacture was the smartphone itself, affirming the full $539 million award. This ruling has had lasting implications for how design patent risk is assessed in the consumer electronics industry and beyond.
Pharma IP FTO Analysis
This case highlights critical IP risks in pharmaceutical product development. Choose your next step:
📋 Understand This Case’s Impact in Pharma IP
Learn about the specific risks and implications from this litigation.
- View 1 patent (US 8,133,893 B2) in this technology space
- See which companies are most active in CNS IP
- Understand claim construction patterns for purified compounds
🔍 Check My Drug Product’s Risk
Run a comprehensive FTO analysis for your own drug formulation or product.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Trazodone Hydrochloride Formulations
1 Patent at Issue
US 8,133,893 B2
Litigation Resolved
Stipulated Dismissal with Prejudice
✅ Key Takeaways
Stipulated dismissals with prejudice in Hatch-Waxman litigation almost universally reflect confidential commercial resolution — analyze settlement structure, not just the dismissal order.
Search related case law →Delaware remains the dominant pharmaceutical patent litigation venue; local counsel selection is a material strategic variable.
Explore precedents →Purified compound and reformulation patents on legacy molecules represent viable, assertable IP — examine claim scope carefully in FTO and validity contexts.
Explore precedents →Frequently Asked Questions
The case involved U.S. Patent No. 8,133,893 B2, covering trazodone and trazodone hydrochloride in purified form, filed under Application No. US 12/513,048.
Both parties stipulated to dismissal under Fed. R. Civ. P. 41(a)(1)(A)(ii) and 41(c), eliminating all claims and defenses with no cost awards — strongly indicating a confidential commercial resolution.
No precedential claim construction or validity ruling was issued. However, ACRAF’s willingness to litigate signals continued enforcement of its purified trazodone IP, which remains relevant to any generic manufacturer pursuing ANDA approval for trazodone hydrochloride.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- PACER — Case No. 1:23-cv-00295, U.S. District Court for the District of Delaware
- USPTO Patent Center — U.S. Patent No. 8,133,893 B2
- CourtListener — Related Delaware Pharmaceutical Patent Decisions
- Cornell Legal Information Institute — Fed. R. Civ. P. 41
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.